Drugs / PSA: 154-163 (155L)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00109811 | Mar 2005 → Sep 2007 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSA: 154-163 (155L) | “The trial was a single dose-level, phase 2 pilot trial of 1 mg of PSA: 154-163 (155L) emulsified with adjuvant (Montanide ISA-51).” PMID 19483644 ↗ Jul 2009 |
| Action | Deplete | “Vaccines made from peptides may help the body build an effective immune response to kill tumor cells” NCT00109811 ↗ |
| Modality | Vaccine | “We conducted a clinical trial of peptide prostate specific antigen (PSA): 154-163 (155L) vaccination in human leukocyte antigen (HLA)-A2 patients” PMID 19483644 ↗ Jul 2009 |
| Route | Subcutaneous | “Given subcutaneously” NCT00109811 ↗ |